Christopher Mjaanes, MD
Allergy & Immunology · Neenah, WINPI 1972660306
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,825 of the $5,912 with a category attached, or 64.7%. Genentech USA, Inc. accounts for 75.8% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $4,649, more than ten times the $224 reported in 2019.
Across 75 payments — averaging $78.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$4K
- AstraZeneca$506
- Pfizer$153
- Sanofi$120
- GSK$58
- Alk-abello, Inc$57
- plus $534 from 15 others
What the payments were for
- Consulting fees$3,82565%
- Food & beverage$2,02234%
- Education$651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 8 | $4,484 |
| AstraZeneca | 18 | $506 |
| Pfizer | 8 | $153 |
| Sanofi | 6 | $120 |
| GSK | 4 | $58 |
| Alk-abello, Inc | 3 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| CSL Behring | 3 | $54 |
| Amgen | 2 | $48 |
| Octapharma USA, Inc. | 2 | $46 |
| Incyte Corporation | 2 | $43 |
| Boehringer Ingelheim | 2 | $39 |
| Biocryst US Sales Co., LLC | 2 | $35 |
| Blueprint Medicines Corporation | 1 | $35 |
| Aimmune Therapeutics, Inc. | 2 | $32 |
| AbbVie | 2 | $29 |
| Mylan Specialty L.p. | 1 | $21 |
| Circassia Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,912 in reported general payments places this provider in the 85th percentile of 55 allergy & immunology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 99 | $365,632 |
| Dupixent PenDupilumab | 36 | $167,453 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $84,641 |
| XembifyImmune Globulin,gamma(Igg)klhw | 43 | $77,828 |
| Dupixent SyringeDupilumab | 12 | $42,564 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $28,867 |
| Spiriva RespimatTiotropium Bromide | 13 | $14,169 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 13 | $12,373 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 28 | $8,405 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 48 | $7,979 |
| Epinephrine | 35 | $7,975 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,460 |
| Arnuity ElliptaFluticasone Furoate | 16 | $5,979 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $5,361 |
| Qvar RedihalerBeclomethasone Dipropionate | 13 | $4,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $58 | $119,487140 claims |
| Boehringer IngelheimSpiriva Respimat | $39 | $14,16913 claims |
| AstraZenecaSymbicort | $506 | $6,46015 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $14 | $4,21713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 55 allergy & immunology providers in Wisconsin.
Other allergy & immunology in Neenah
- William BusseMadison$928K
- Jared DarveauxOnalaska$287K
- Don BuksteinFitchburg$257K
- Allan LuskinMadison$51K
- Monica VasudevSheboygan$25K
- Heidi ZafraMilwaukee$7K
- Sudip RingwalaKenosha$6K
- Steven CohenWest Allis$5K
- Karen KonzAppleton$4K
- Lakshmi Gopalakrishnan NairGreen Bay$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.